Prior MRI-imaging impact of patients submitted to brachytherapy for prostate cancer.

INTRODUCTION: Brachytherapy for the treatment of prostate cancer is a well-established option. Use of Multiparametric Magnetic Resonance Imaging (mpMRI) for staging and diagnosis of prostate cancer has come to change the current paradigm. In this study we aim to assess the impact of performing mpMRI to evaluate the presence of extracapsular lesions before brachytherapy in patients with prostate cancer concerning biochemical recurrence and time to nadir. METHODS: Review data from 73 patients submitted to brachytherapy. The following factors were evaluated: age, initial PSA, MRI local staging results, ISUP, nadir, time to nadir, PSA at one-year, biochemical recurrence, and time to recurrence. RESULTS: Median age was 68 years (51-72) and median follow-up 53 months (30-72). Concerning imaging modality 30,1% (n = 22) patients performed mpMRI. In the mpMRI group, 90.9% (n = 20) had at least one suspect lesion on mpMRI. Time to nadir was 27 months (3-64) in patients where mpMRI was not performed and 23.5 months (2-48) in patients submitted to mpMRI (P = .244). The median value of nadir was 0.42 ng/mL (<0.001-2) in patients submitted to mpMRI and vs 0.28 ng/mL (<0.001-4) in patients without MRI (P = .062) Recurrence utilizing Phoenix criteria was 9% (n = 2) in patients with MRI and 9.2% (n = 5) without mpMRI (P = .456), median follow-up of 43 months (12-72) for the MRI group with 58 months (30-78) for the non-mpMRI group. Both groups were statistically similar. CONCLUSION: Our results allow us to conclude that in our series MRI did not influence biochemical recurrence, time to nadir, or nadir value.

Níveis de treonina digestível para suínos machos castrados, de alto potencial genético para deposição de carne, na fase de terminação / Digestible threonine levels for high genetic potential lean deposition finishing barrows

Avaliou-se o efeito de níveis de treonina digestível em rações sobre o desempenho e características de cacaça de suínos machos castrados, selecionados geneticamente, para deposição de carne na carcaça, na fase de terminação. Foram utilizados 70 animais, com peso inicial de 59,00+1,25kg, distribuídos em delineamento experimental de blocos ao acaso, com cinco tratamentos, sete repetições e dois animais por unidade experimental, sendo que na distribuição dos animais, foi adotado como critério o peso inicial. Os tratamentos foram níveis de treonina na ração (0,480; 0,504; 0,528; 0,554 e 0,572 por cento de treonina digestível). Não houve efeito (P>0,05) dos tratamentos sobre o ganho de peso, consumo de ração e conversão alimentar. Os níveis de treonina digestível não influenciaram (P>0,05) a porcentagem de carne e a espessura de toucinho na carcaça. Conclui-se que o nível de 0,480 por cento de treonina digestível, correspondente a relação de treonina digestível:lisina digestível de 60 por cento, atendeu as exigências de suínos machos castrados de alto potencial para deposição de carne na carcaça dos 60 aos 95kg.

An experiment was carried out to determine the effects of digestible threonine levels in ration on the performance and carcass traits of hogs genetically selected for lean deposition at finishing. Seventy barrows averaging an initial weight of 59.00+1.25kg were distributed in a randomized experimental block design with five treatments and seven replicates, being two animals per experimental unit. Initial weight was adopted as a criterion for animal distribution in the treatments, which were the levels of digestible treonine in the diet (0.480; 0.504; 0.528; 0.554; and 0.572 percent). No effect (P>0.05) was observed among the treatments on daily weight gain, daily feed intake, and feed conversion. Digestible threonine levels did not influence (P>0.05) lean and backfat thickness percentage. It can be concluded that the level of 0.480 percent of digestible treonine, corresponding to the rate digestible treonine:lysine 60 percent, supplied the requirments of high potential lean deposition barows from 60 to 95kg.